2023-09-01 2024-08-31 false Capium Accounts Production 1.1 14284456 2023-09-01 2024-08-31 14284456 bus:FullAccounts 2023-09-01 2024-08-31 14284456 bus:FRS102 2023-09-01 2024-08-31 14284456 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 14284456 bus:SmallCompaniesRegimeForAccounts 2023-09-01 2024-08-31 14284456 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 14284456 2023-09-01 2024-08-31 14284456 2024-08-31 14284456 bus:RegisteredOffice 2023-09-01 2024-08-31 14284456 core:WithinOneYear 2024-08-31 14284456 core:AfterOneYear 2024-08-31 14284456 1 2023-09-01 2024-08-31 14284456 bus:Director1 2023-09-01 2024-08-31 14284456 bus:Director1 2024-08-31 14284456 bus:Director1 2022-08-09 2023-08-31 14284456 bus:Director2 2023-09-01 2024-08-31 14284456 bus:Director2 2024-08-31 14284456 bus:Director2 2022-08-09 2023-08-31 14284456 2022-08-09 14284456 bus:LeadAgentIfApplicable 2023-09-01 2024-08-31 14284456 2022-08-09 2023-08-31 14284456 2023-08-31 14284456 core:WithinOneYear 2023-08-31 14284456 core:AfterOneYear 2023-08-31 14284456 bus:EntityAccountantsOrAuditors 2022-08-09 2023-08-31 14284456 bus:OrdinaryShareClass1 2023-09-01 2024-08-31 14284456 bus:OrdinaryShareClass1 2024-08-31 14284456 bus:OrdinaryShareClass1 2022-08-09 2023-08-31 14284456 bus:OrdinaryShareClass1 2023-08-31 14284456 core:OtherResidualIntangibleAssets 2023-09-01 2024-08-31 14284456 core:OtherResidualIntangibleAssets 2024-08-31 14284456 core:OtherResidualIntangibleAssets 2023-08-31 14284456 core:CostValuation core:Non-currentFinancialInstruments 2024-08-31 14284456 core:CostValuation core:Non-currentFinancialInstruments 2023-08-31 14284456 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-08-31 14284456 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-08-31 14284456 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-08-31 14284456 core:Non-currentFinancialInstruments 2024-08-31 14284456 core:Non-currentFinancialInstruments 2023-08-31 14284456 core:ShareCapital 2024-08-31 14284456 core:ShareCapital 2023-08-31 14284456 core:SharePremium 2024-08-31 14284456 core:SharePremium 2023-08-31 14284456 core:RetainedEarningsAccumulatedLosses 2024-08-31 14284456 core:RetainedEarningsAccumulatedLosses 2023-08-31 14284456 dpl:Item1 2023-09-01 14284456 dpl:Item1 2024-08-31 14284456 dpl:Item1 2022-08-09 14284456 dpl:Item1 2023-08-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14284456
England and Wales

 

 

 

MOLECULE PHARMA LIMITED



Unaudited Financial Statements
 


Period of accounts

Start date: 01 September 2023

End date: 31 August 2024
Directors Pranav Pradipkumar Shah
Swapnkumar Mukeshbhai Patel
Registered Number 14284456
Registered Office 231 Kenton Road
Harrow
Middlesex
HA3 0HD
Accountants 3E'S Accountants Limited
231 Kenton Road
Harrow
Middlesex
England
HA3 0HD
1
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Intangible fixed assets 3 1,435,500    1,542,750 
1,435,500    1,542,750 
Current assets      
Debtors 4 104,213    10,953 
Cash at bank and in hand 188,742    42,543 
292,955    53,496 
Creditors: amount falling due within one year 5 (98,098)   (16,795)
Net current assets 194,857    36,701 
 
Total assets less current liabilities 1,630,357    1,579,451 
Creditors: amount falling due after more than one year 6 (1,655,147)   (1,733,914)
Net assets (24,790)   (154,463)
 

Capital and reserves
     
Called up share capital 7 1,016    1,000 
Share premium account 8 79,984   
Profit and loss account (105,790)   (155,463)
Shareholders' funds (24,790)   (154,463)
 


For the year ended 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the board of directors on 31 May 2025 and were signed on its behalf by:


-------------------------------
Pranav Pradipkumar Shah
Director
2
General Information
Molecule Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 14284456, registration address 231 Kenton Road, Harrow, Middlesex, HA3 0HD.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the statement of financial position date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All foreign exchange differences are included to the income statement.
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Licences and patents
Licences and patents are stated at cost less amortisation. Amortisation is calculated on a straight line basis @ 6.5%.
2.

Average number of employees

Average number of employees during the year was 2 (2023 : 2).
3.

Intangible fixed assets

Cost Other intangible assets   Total
  £   £
At 01 September 2023 1,650,000    1,650,000 
Additions  
Disposals  
At 31 August 2024 1,650,000    1,650,000 
Amortisation
At 01 September 2023 107,250    107,250 
Charge for year 107,250    107,250 
On disposals  
At 31 August 2024 214,500    214,500 
Net book values
At 31 August 2024 1,435,500    1,435,500 
At 31 August 2023 1,542,750    1,542,750 


4.

Debtors: amounts falling due within one year

2024
£
  2023
£
Trade Debtors 93,990   
Other Debtors 10,223    10,953 
104,213    10,953 

5.

Creditors: amount falling due within one year

2024
£
  2023
£
Trade Creditors 3,720    960 
Taxation and Social Security 92,628    15,585 
Other Creditors 1,750    250 
98,098    16,795 

6.

Creditors: amount falling due after more than one year

2024
£
  2023
£
Other Creditors 1,655,147    1,733,914 
1,655,147    1,733,914 

7.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
10,000 Ordinary shares of £0.10 each 1,000    1,000 
1,000    1,000 

8.

Share premium account

2024
£
  2023
£
Equity Share Premium - New Issue 79,984   
79,984   

3